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Abstract: Glycosyltransferases carry out important cellular functions in species ranging from 
bacteria to humans. Despite their essential roles in biology, simple and robust activity assays that 
can be easily applied to high-throughput screening for inhibitors of these enzymes have been 
challenging to develop. Here we report a bead-based strategy to sensitively measure the group 
transfer activity of glycosyltransferases using simple fluorescence measurements, without the 
need for coupled enzymes or secondary reactions. We validate the performance and accuracy of 
the assay using O-GlcNAc Transferase (OGT) as a model system through detailed Michaelis-
Menten kinetic analysis of various substrates and inhibitors. Optimization of this assay and 
application to high-throughput screening enabled screening for inhibitors of OGT, leading to a 
novel inhibitory scaffold. We believe this assay will prove valuable not only for the study of OGT, 
but also more widely as a general approach for the screening of glycosyltransferases and other 
group transfer enzymes. 
 
Keywords: Glycosyltransferase, enzyme assay, high-throughput screening, O-GlcNAc, 
glycoprotein, fluorescent substrates  
Table of contents figure 
 
 
A robust fluorescence-based assay accurately reports on the sugar transfer activity of 
glycosyltransferases. This assay is amenable to high-throughput screening and should be 
applicable to a diverse set of group transfer enzymes. We validate this assay through screening 





 The large superfamily of glycosyltransferases (GTs) are responsible for the assembly of 
the diverse glycoconjugates found throughout every kingdom of life[1,2]. The increasing recognition 
of the roles played by glycans, including in regulating human physiology, are raising interest in 
these enzymes and the associated development of chemical approaches to monitor and modulate 
their activities[3–6]. One area of emerging interest is the development of reliable 
glycosyltransferase enzyme assays for characterizing their activities[7,8], alongside with their use 
in high throughput screening efforts to identify small molecule inhibitors[4,9]. The standard activity 
assay that directly measures glycosyl transfer relies on the enzyme catalyzed transfer of 
radiolabeled sugar units from nucleotide sugar donor substrates to a suitable acceptor substrate, 
which is then followed by liquid scintillation detection[9–11]. The requirement for using radioactive 
materials, however, detracts from the wide uptake and applicability of such assays and has 
spurred interest in developing new assays for various GTs.  
Among the various strategies that have been pursued are coupled enzyme activity assays 
that, for example, include measuring the release of nucleoside diphosphate leaving groups via 
spectrophotometric detection of reduced nicotinamide adenine dinucleotide (NADH) or the 
consumption of nucleoside diphosphates (NDPs) to drive formation of adenosine triphosphate 
(ATP) that is then detected by bioluminescence[12,13]. ELISA-based luminescent approaches have 
also been developed, whereby transfer of a monosaccharide unit is detected by a tagged pan-
specific antibody[14]. Additionally, a coupled fucosyltransferase assay, in which transfer of a fucose 
to a fluorogenic oligosaccharide prevents a glycoside hydrolase from acting to release the 
fluorophore reporter was developed recently[15]. Various fluorescence polarization (FP) assays 
have also been advanced. Walker and colleagues, who pioneered work on screening for inhibitors 
of O-GlcNAc Transferase (OGT), used a fluorescein-linked UDP-GlcNAc analogue that served as 
a probe for an FP binding assay[16]. Paulson and colleagues expanded further on this approach 
by developing fluorescently-labeled nucleotide sugar donors that are substrates for a sialyl and 
fucosyltransferase, resulting in increased polarization when transferred to a glycoprotein 
substrate[4]. Withers and co-workers extended this approach to create an “FP-Tag” assay which 
uses an azide-labeled glycosyl donor that is transferred to a fluorescent oligosaccharide and 
conjugated to biotin via click chemistry, permitting pull-down with streptavidin and subsequent FP 
detection[17]. 
While these methods represent notable advancements, the use of coupled assays 
requiring a secondary enzyme or chemical transfer step is not ideal as this introduces an 
additional step at which test materials can interfere. In HTS assays in particular, such interference 
can yield a high number of false positives resulting from inhibition of the secondary processes 
instead of the primary target[18]. FP assays also do not directly measure enzymatic activity and 
compounds that disrupt binding through non-specific means, such as binding or displacing the 
fluorophore non-specifically from the surface of a protein, can similarly yield false positives [19,20]. 
Additionally, FP assays require high concentrations of protein and are sometimes incapable of 
detecting weak interactions[20]. Given these considerations, we aimed to develop a simple and 
direct quantitative fluorescence-based assay that would provide high-quality kinetic data using 
only small amounts of enzyme without the need for downstream coupling enzymes, bioorthogonal 
reactions, or detection reagents. This concept has been applied to binding processes, notably for 
fluorescently-labeled aptamers[21], but surprisingly has never, to our knowledge, been applied to 
group transfer enzymes such as GTs. However, we expected that such an assay might prove 
useful for ongoing efforts to study the enzymatic activity of GTs toward various substrates as well 
as to characterize molecules that could modulate the activity of these enzymes. Moreover, we 
envisioned that adaptation of such an assay to a format compatible with high-throughput 
screening would facilitate identifying new leads for GTs that could be suitable for development as 
tool compounds.  
As a model system of high interest with which we have experience, we focused on the 
enzyme O-GlcNAc Transferase (OGT), which catalyzes the installation of a single O-linked N-
acetylglucosamine (O-GlcNAc) to the hydroxyl groups of serine and threonine residues of nuclear 
and cytosolic proteins[22][23]. This reversible modification has been identified on hundreds of protein 
substrates[24] and regulates central cellular processes such as transcription[25], protein stability 
cellular stress response[26], and cell cycle regulation[27]. Moreover, dysregulated OGT activity has 
been implicated in many signalling pathways related to cancer progression and tumor growth. 
Indeed, mounting evidence suggests that OGT is a promising therapeutic target for various 
cancers[28–31]. Furthermore, consistent with the high interest in this enzyme, previous efforts to 
screen OGT have been pursued and yielded various leads [16,32–34]. Improvement of these leads 
has, however, proven challenging. Walker and co-workers were the first to undertake this, 
carrying out two separate screens for OGT inhibitors using their FP displacement assay as well 
as a coupled protease protection assay[16,32]. These efforts resulted in a class of quinolone-6-
sulfonate-based (Q6S) compounds,[33] which were recently advanced to yield promising 
compounds with nanomolar in vitro potency[34]. However, many of the inhibitors arising from these 
screens adversely affect cell viability and likely suffer from significant off-target effects[35]. Efforts 
to improve the potency of the Q6S scaffold over the past decade have yielded good success, 
however, the resulting lead has a high molecular weight that may impair brain permeability and 
other in vivo applications. Ideally, as has often proven useful, the identification and advancement 
of new and diverse scaffolds that can be optimized are needed in order to ultimately identify 
complementary tool compounds for in vivo use. 
Despite its importance in contributing to cellular physiology, and the complexity of the 
mechanisms by which OGT function must accordingly be regulated, studying this enzyme remains 
challenging in part because of a lack of convenient assays and chemical biology tools[14,36]. Here 
we describe the development of a simple and sensitive fluorescence-based assay that directly 
and precisely measures glycosyl transfer catalyzed by OGT. We validate this assay and illustrate 
its amenability to high-throughput screening in microplate format. After implementing the assay in 
a trial screen, we identify a known bioactive inhibitor that also antagonizes OGT and confirm its 
ability to directly inhibit OGT.  
 
Results and Discussion 
 OGT is able to use uridine diphosphate N-acetylglucosamine (UDP-GlcNAc, 1) analogues 
having various 2-N-acyl groups in place of the 2-acetamido substituent[16,37]. UDP-GlcNAc 
analogues bearing large fluorophores at this 2-position were previously found only to bind to OGT 
rather than be turned over[16], however, judicious selection of linkers revealed appending a 
nitrobezoxadiazole (NBD) fluorophore to this position was tolerated.[37]  Based on these 
observations, we reasoned that using suitable linkers might enable incorporation of other 
fluorophores having different physicochemical and photophysical properties. We therefore 
elected to prepare a BODIPY-FL dye linked using an N-hexanoyl linker (2, UDP-GlcN-BODIPY, 
Figure 1). We were attracted to this option because of the relatively small size of this fluorophore 
in combination with its desirable photophysical properties, including high photostability and 
quantum yield. We therefore prepared UDP-GlcN-BODIPY (Scheme 1) by modification of 
established methods starting with glucosamine hydrochloride (3). After protection of the hydroxyl 
groups and masking of the amine as an azide functionality, we installed the anomeric phosphate 
using MacDonald phosphorylation conditions[38]. The acetate protecting groups were then 
removed, the azide reduced, and the resulting amine coupled to BODIPY-FL caproic acid using 
HBTU peptide coupling conditions. Finally, the desired nucleoside, UDP-GlcN-BODIPY, was 
prepared by coupling of intermediate 8 with UMP-morpholidate. We found after exploration of 
several routes that installation of the fluorophore prior to the morpholidate coupling permitted 
facile purification by silica chromatography and enabled suitable scale-up of this reaction. Details 
regarding the synthesis, including preparation of BODIPY-FL caproic acid, are included in the 
Supporting Information (SI). 
 
Figure 1: Structure of UDP-GlcNAc (1), the natural donor substrate used by OGT, and the 
fluorescent analogue UDP-GlcN-BODIPY (2). 
 
 
Scheme 1: Synthetic route towards UDP-GlcN-BODIPY (2). Reagents and conditions: i) 
imidazole-1-sulfonyl azide•HCl, CuSO4•5H2O, K2CO3, MeOH, 2 h, 92%; ii) Ac2O, pyridine, 10 h, 
98%; iii) H3PO4 (s), vacuum, 80 mTorr, 60°C, 44%; iv) NaOMe, MeOH, 92%; v) H2, Pd/C, MeOH, 
98%; vi) BODIPY-FL-X, HBTU, DIPEA, DMF, 37%; vii) UMP-morpholidate, N-
methylimidazole•HCl, DMF, 45%. 
 
With UDP-GlcN-BODIPY (2) in hand, we assessed its competency as a donor substrate 
for OGT using a well studied OGT peptide substrate derived from Casein Kinase II (CKII). Using 
this TAMRA-conjugated CKII peptide (TAMRA-NH-YPGGSTPVSSANMM-OH) we observed, 
using HPLC-based analysis, a modest level of transfer of the GlcN-BODIPY moiety to the peptide 
that was confirmed by mass spectrometry (MS) analysis of the reaction products (Figure S1). To 
understand the basis for molecular recognition of UDP-GlcN-BODIPY by OGT and how this 
enzyme tolerated this larger BODIPY moiety, we crystallized a truncated construct of OGT in 
complex with substrate UDP-GlcN-BODIPY[39]. This data (Table S1) enabled building a clear 
model revealing how the caproic acid linker is sufficiently long for the BODIPY fluorophore to 
completely extrude from the active site, causing minimal disruption of the active site architecture 
(Figure 2, Figure S2). Strong difference density was observable at the end of the linker and this 
is likely attributable to the BODIPY fluorophore, however, the fluorophore cannot be modelled 
with confidence (Figure S3). This ambiguity is likely a result of the BODIPY fluorophore occupying 
multiple conformations. A second BODIPY fluorophore can be modelled near the substrate 
(Figure 2), but this may stem from OGT-catalyzed hydrolysis of UDP-GlcN-BODIPY or, 
alternatively, a second molecule of substrate being present in proximity to the active site. The 
uridine and pyranose ring are positioned within the active site in a manner similar to those 
structures previously reported with bound UDP, except that there is a slight rotation in the α-
phosphate. This may stem from the altered position of Q839 leading to rotation of the α-phosphate 
to within hydrogen bonding distance of T921.  
 
Figure 2: Crystallographic structure of OGT with substrate 2 bound. The OGT active site (grey) 
is depicted as a surface representation demonstrating how it is able to accommodate the caproic 
acid linker of the substrate (light blue). The fluorophore portion of a second substrate molecule 
can be modeled nearby. 
 
Encouraged by these results, we set out to implement a convenient microplate-based 
assay (Figure 3). We envisioned we could incubate a biotinylated peptide as an OGT acceptor 
substrate along with glycosyl donor 2 and initiate the reaction through the addition of recombinant 
OGT to generate a BODIPY-modified glycopeptide. The modified and unmodified peptides can 
then be captured on streptavidin-coated surfaces after specified times. In this way, we reasoned 
we could directly monitor the glycosyl transfer catalyzed by OGT. We set out to use the same 
CKII peptide as noted above, which is a well-studied substrate of OGT and is readily prepared by 
solid-phase peptide synthesis, in its biotinylated form (Table S3) as a convenient acceptor 
substrate for the assay. The N-terminal biotin handle permitted immobilization on streptavidin-
coated surfaces, which in turn facilitated subsequent washing to remove unreacted UDP-GlcN-
BODIPY. The fluorescent signal remaining after washing could thus correspond to the BODIPY-
modified glycopeptide, which can be obtained using a standard microplate reader (Figure S4). In 
this way, a measure of direct glycosyl transfer to a peptide acceptor can be obtained and a wide 
range of parameters can be varied to optimize the sensitivity of the assay. We found that both 
commercial streptavidin-coated microplates and streptavidin-coated magnetic beads could be 
used as a capture medium for the assay. We decided to use magnetic beads for subsequent 
experiments, since this format provided greater signal over background.  
 
Figure 3: Methodology for activity-based OGT assay and inhibitor screen. Incubation of a peptide 
substrate with OGT results in transfer of a fluorescent sugar analogue. Immobilization on 
streptavidin-coated beads followed by washing permits direct measurement of transfer by 
fluorescence in 96- or 384-well plate format. 
 
We recognized that one key factor in assay reproducibility would be to stop the assay at 
a defined time point by preventing further O-GlcNAc incorporation during the biotin-streptavidin 
capture. We reasoned that UDP, which is known to competitively inhibit OGT (Ki of 1.3 µM)[40], 
could be used to stop the enzymatic reaction prior to washing. Using this assay, we found that 2 
mM UDP completely inhibits the reaction when concentrations of UDP-GlcN-BODIPY in the assay 
were equal or less than 25 µM (Figure S5). After optimizing the assay conditions and 
concentrations of both substrates and OGT, we found that the assay produced fluorescence 
signals 50-fold greater than control reactions performed either in the presence of 2 mM UDP or 
in the absence of CKII peptide acceptor. By monitoring the reaction as a function of time at various 
concentrations of 2, we were able to perform Michaelis-Menten analyses to obtain kinetic 
parameters for both the UDP-GlcN-BODIPY donor and CKII peptide acceptor (Figures 4A and 
4B).  As expected, the presence of the BODIPY fluorophore and linker impaired the rate of the 
reaction. This effect was quite modest, however, since the kcat/KM value for UDP-GlcN-BODIPY 
when using CKII as the acceptor was found to be ~7-fold lower than the value previously reported 
for {3H}-UDP-GlcNAc when using a similar CKII peptide acceptor in a radioactivity-based assay 
(Table S2)[39]. Interestingly, the KMapp for UDP-GlcN-BODIPY (KM = 2.9 ± 0.3 µM) was found to be 
similar to than reported for UDP-GlcNAc (KM =2.3 ± 0.4 µM) and the reduction in kcat value was 
approximately 6-fold (0.05 ± 0.002 min-1) as compared to the value measured for UDP-GlcNAc 
(0.29 ± 0.01 min-1) (Table S2). The similar KMapp values observed for UDP-GlcNAc and UDP-GlcN-
BODIPY, coupled with the structural data, suggest that OGT tolerates binding of the fluorophore 
and linker in its active site, and that the reduction in second order rate constant is largely driven 
by other factors affecting catalytic transfer to the peptide. We note that in the binary complex we 
observe the linker of compound 2, and by extension the unmodeled fluorophore, reaches across 
the active site cleft to where the incoming peptide acceptor has been observed in ternary 
complexes[39]. We therefore reason that the linker or fluorophore may partially hinder binding of 
peptide acceptors, which may in turn explain the reduction in kcat values observed using UDP-
GlcN-BODIPY.  
 
Figure 4: UDP-GlcN-BODIPY (2) is a substrate for OGT, permitting convenient determination of 
kinetic parameters. A, Michaelis-Menten curve of glycosyl donor 2 at saturating concentrations of 
peptide acceptor (>10-fold above KM). B, Michaelis-Menten curve of Biotin-CKII peptide acceptor 
in the presence of saturating concentrations of glycosyl donor. C, Lineweaver-Burk plot showing 
inhibition of OGT by UDP at varying concentrations of glycosyl donor 2, with a calculated Ki value 
of 6.1 µM. Error bars represent S.E.M. of triplicate measurements. 
 
Next, having established initial conditions, we evaluated a small panel of biotinylated 
peptide acceptors that had been previously identified as OGT substrates (Figure S6). A TAK1-
binding protein 1 (TAB-1) peptide[41] was found to have comparable kinetic parameters to those 
measured for CKII, whereas a peptide derived from host cell factor 1 (HCF-1)[42] was a 22-fold 
better substrate as determined by comparing its kcat/KM value to that obtained for CKII (Table S3). 
We therefore chose this peptide for subsequent studies since it produced greater signal to noise, 
even at lower concentrations of enzyme. We next investigated the utility of this assay for analysis 
of inhibitors, both in performing IC50 studies as well as for determining mode-of-inhibition and Ki 
values (Figure 4C). The inhibition of OGT using UDP and various concentrations of UDP-GlcN-
BODIPY in the presence of saturating concentrations of the CKII peptide acceptor gave a Ki value 
of 6.9 ± 0.7 µM, which is in close agreement with previous reports using the radioactivity-based 
glycosyl transfer assay[43]. Lineweaver-Burk graphical analysis of this data also clearly showed 
the expected pattern of competitive inhibition. In contrast, when inhibition was assessed over 
varying concentrations of peptide acceptor, a non-competitive pattern of inhibition was obtained 
with respect to UDP (Figure S7). Importantly, these comparisons demonstrated the utility of our 
assay for the convenient determination of Michaelis-Menten parameters across various 
substrates and conditions as well as in detailed inhibition studies to establish the site at which an 
inhibitor binds within the active site of OGT. 
Having demonstrated the applicability and high sensitivity of our assay in kinetic 
experiments, we next adapted the assay for use in 384-well microplates to enable economic use 
of materials as well as with a view to apply it to high-throughput screening for small-molecule 
inhibitors of OGT. The concentration of donor and acceptor substrates used were at 
approximately KM for each substrate in order to make the assay sensitive to compounds that might 
compete for binding at either the donor or acceptor binding site. The reaction buffer was also 
changed to include 0.01% (v/v) Triton X-100 so as to reduce potential non-specific inhibition by 
compounds prone to colloidal aggregation, which is a common problem encountered when 
performing screening assays[19], and we reduced the total reaction volume to 25 µL. These 
changes had no significant effect on assay behaviour. We also optimized the automated plate 
washing protocol to minimize disruption of the streptavidin-coated magnetic beads in the wells by 
by introducing a short delay between wash cycles, which allows the beads to settle. We also 
adjusted the height at which aspiration was performed above the well base and found that a 6 
mm height struck a balance between effective washing of the beads without aspirating them out 
of the wells, resulting in satisfactory signal-to-noise (Figure S8). Although we recognized that 
interference in screening could arise from antagonists that disrupt the biotin-streptavidin 
interaction, felt this extremely high affinity interaction would be one of the most robust binding 
interactions since the resulting complex has a half-life in the order of hours[44]. Accordingly, we 
reasoned that a 30 minute incubation time for capture would be sufficient to avoid interference. 
To test this assumption, we showed that desthiobiotin, a biotin analogue with a KD of 
approximately 10-11 M towards streptavidin[45], at concentrations of up to 25 µM did not influence 
the performance of the assay (Figure S9). This result suggested that the capture of the 
biotinylated substrate would not be impaired by even potent streptavidin antagonists, including 
less potent candidate antagonists that might be encountered during HTS.  
Using this optimized assay, we next set out to validate this assay in high-throughput format 
by performing a trial screen. As a proof of concept, we used a targeted library containing 4480 
known bioactive compounds obtained commercially from TargetMol Corp (Wellesley Hills, MA). 
We were able to conduct this assay over the course of one day in a fully automated format, which 
validated the suitability of this assay for high-throughput screening. The overall Z’ score obtained 
for the assay was 0.67 (Figure 5) and we observed a clear Gaussian distribution of compound 
activities. Because the discovery of glycosyltransferase inhibitors from screening libraries has 
proved difficult, and identifying tractable inhibitors from past efforts to screen OGT has been 
challenging, we chose to screen using a relatively high compound concentration of 100 µM. This 
translated to an overall hit rate of 6.1%, with hits being defined as those compounds resulting in 
OGT activity that was less than three standard deviations from the mean of our 100% activity 
control, which corresponds to 58.5% enzyme activity relative to the positive control vehicle only 
standards. Of the initial 275 hits we identified from primary screening, a short-list of 88 compounds 
for re-testing in triplicate was prepared by first excluding compounds in the library with a high 
likelihood of pan-assay interference (PAINS)[46] such as those that might function as detergents, 
or have fluorescent moieties or reactive functional groups. From these confirmed hits, we further 
prioritized 11 compounds that displayed desirable properties and obtained them commercially to 
determine inhibition constants. Compounds were also subjected to a secondary thermal shift 
assay using differential scanning fluorimetry (DSF)[47] to confirm direct binding of the materials to 
the enzyme. 
 
Figure 5: Summary of screening results against OGT from a targeted library of 4480 known 
chemical probes. Compounds were screened at a final concentration of 100 µM. µpos corresponds 
to the mean signal of uninhibited positive control wells. µneg corresponds to the mean signal of 
negative control wells in the absence of enzyme. Hits were defined as compounds resulting in 
less than 58.5% OGT activity, corresponding to at least three standard deviations from the 
positive control signal for activity. Prioritized hits which were selected for follow-up studies are 
marked as blue circles. Structures of these compounds and bioassay results are listed in the 
Supporting Information (Table S4). 
Using our secondary binding assay in combination with our activity assay, we rejected the 
majority of our selected 11 hit compounds due to non-specific behaviour such as detergent 
sensitivity, solubility issues, or failure to replicate activity in both assay formats. However, we 
identified one compound (Dyngo®-4a, 9, Table 1) which displayed low-micromolar affinity towards 
OGT in both our primary enzyme assay and secondary DSF assay. This compound was initially 
developed as part of a chemical family of inhibitors targeting the dynamin GTPase, an enzyme 
responsible for the rate-limiting scission of vesicles at the plasma membrane that occurs in many 
forms of endocytosis just prior to vesicle internalization[48,49]. Notably, Dyngo-4a represents a great 
improvement over its predecessor, known as Dynasore, both in terms of its potency against 
dynamin and consequent effects on endocytosis. Furthermore, Dyngo-4a exhibits desirable 
chemical properties including a lack of detergent sensitivity[49,50]. Given its utility in the inhibition 
of endocytosis, Dyngo-4a and other dynamin inhibitors have demonstrated efficacy in multiple 
proof-of-concept disease studies[51,52]. We were surprised to find that Dyngo-4a, which is a 
comparatively small molecule, also bound and inhibited OGT with an IC50 value of 6.3 ± 0.7 µM 
(Figure 6A). Using detailed kinetic assays, we showed that Dyngo-4a inhibits OGT non-
competitively with respect to both the glycosyl donor and the peptide acceptor (Figure S10). Given 
the phenolic nature of Dyngo-4a, we speculated that it could lead to time dependent inactivation 
of OGT, but our kinetic studies show no time-dependent loss of activity, suggesting inhibition of 
OGT by Dyngo-4a is reversible (Figure S11). Additionally, the presence of 1 mM DTT in the assay 
buffer reduces the likelihood of oxidation of the phenolic hydroxyls to a quinone moiety. 
Furthermore, the positive shift in melting temperature observed when OGT is incubated with 
Dyngo-4a at a concentration of 10 µM, coupled with the lack of detergent sensitivity and the Hill 
slope of -1, indicates that the compound directly binds and stabilizes the protein, rather than 
inactivating the enzyme non-specifically (Figure 6A and 6B).  
 
Figure 6: Dyngo-4a binds and inhibits OGT with low-micromolar affinity. A, Concentration-
response showing Dyngo-4a inhibition of recombinant OGT. Error bars represent S.E.M. (n=4). 
B, DSF-based thermal shift assay showing thermal stabilization of the OGT catalytic domain in 
the presence of 10 µM Dyngo-4a. Dashed lines indicate S.E.M (n=3). A temperature ramp of 25°C 
to 95°C was used at a gradient of 0.05°C/sec. 
 
Although we were encouraged by the ability of Dyngo-4a to inhibit OGT, we recognized that this 
off-target inhibition would complicate future studies of this tool compound, both for potential use 
as an OGT inhibitor but also for use as a dynamin inhibitor. We therefore aimed to identify 
structurally related compounds that would inhibit each target in a selective manner by testing 
previously-synthesized Dyngo-4a analogues against OGT. Through screening of a small library 
of 167 Dyngo-4a analogues, we identified an additional 9 compounds that showed at least 50% 
inhibition against OGT at a concentration of 40 µM (Figure S12). Two of these compounds display 
minimal activity towards dynamin, but largely retain their potency toward OGT (Figure 7). 
Compound 10, which differs from the parent compound by the removal of one hydroxyl group, 
retains an IC50 value for OGT of 19 ± 3 µM (Table 1). Compound 11 displays less potency towards 
OGT but also displays selectivity, as no inhibition towards dynamin was observed at 
concentrations up to 100 µM (Table 1, Figure S13). These compounds should serve as a small 
novel scaffold from which more potent analogues can be derived. Additionally, the results 
obtained here highlight the utility of our assay for the quick identification of Dyngo-4a analogues 
that do not show inhibition towards OGT, suggesting that the development of more potent and 
selective effectors of dynamin activity is also feasible.  
 
 
Figure 7: Screening of a series of Dyngo-4a analogues reveals two additional compounds with 
selectivity for OGT. Concentration response curves show inhibition of recombinant OGT by 
Dyngo-4a (9, black), and structurally related analogues 10 (blue), and 11 (red). Error bars 
















Owing to the important roles played by glycosyltransferases, the development of inhibitors 
of these enzymes is currently a topic of high interest. A prerequisite for successful identification 
of such inhibitors is the development of robust assays for this class of enzymes. Remarkably few 
GT assays are known in which the assay reports directly on the enzyme catalyzed transfer of the 
carbohydrate unit. Here we exploit the substrate tolerance of OGT to develop what is, to our 
knowledge, the first fluorescence-based assay that reports directly on the transfer of the sugar 
unit. Optimization of this assay yields a highly sensitive and accurate assay that can be 
conveniently used to obtain Michalis-Menten kinetic parameters for both substrates and inhibitors. 
This assay is furthermore amenable for use in high-throughput screening. After HTS-based 
discovery of a known endocytosis inhibitor in a screening campaign, we used this assay to rapidly 
assess a family of analogues in order to identify a selective OGT inhibitor. While these leads show 
relatively modest potency, the low molecular weight of these compounds may make them a useful 
starting point to generate tool compounds for OGT and provide a novel scaffold for development 
of more potent analogues. We expect this assay will have great utility, both for routine kinetic 
analysis of OGT activity as well as for additional HTS campaigns for inhibitors of OGT. 
While the substrates used in this assay are tailored for OGT, we note that many 
glycosyltransferases that have been studied in this regard demonstrate tolerance for pendant 




























is likely that similar fluorescent substrates can be developed for other GTs but may require 
optimization of both the type of linker and its site of attachment. Therefore, we believe this assay 
format could be readily adapted to other families of GTs, including those that have already been 
shown to tolerate pendent groups including fucosyltransferases[4,54,55], sialyltransferases[4,55], and 
polypetide GalNAc transferases[56]. Combining the use of such fluorescent donor sugars with 
biotinylated acceptors will permit the study of these other classes of GTs. An advantage of our 
assay is that it is compatible for use with GTs that use non-Leloir glycosyl donors, which cannot 
be monitored by coupled assays that detect nucleotide diphosphate reaction products. 
Additionally, as a screening assay, our approach is capable of robust and efficient HTS and can 
detect weak (>50 µM) binders, which is useful for GTs as these are notoriously difficult to target. 
The ability to screen with low concentrations of enzyme (20 nM), as well as low donor (3 µM) and 
acceptor substrates (10 µM), makes this approach reagent conservative and therefore readily 
feasible for high throughput screening. Notably, this flexibility also permits the design of screens 
that are biased toward a particular type of inhibition – for example, by increasing the concentration 
of one substrate or the other above KM in order to select for non-competitive or allosteric inhibitors. 
We also note that the strategy of directly incorporating the fluorescent reporter to a substrate, 
adding magnetic beads to the reaction wells, and then measuring on-bead fluorescence after 
washing offers a simplified assay design that minimizes reagent transfer and liquid handling steps. 
We therefore expect this general assay format will aid in the mission of discovering improved 
chemical tools for the important superfamily of glycosyltransferases. Finally, we believe that this 
technique will have applications for other group transfer enzymes that are difficult to monitor 
directly including, for example, acyltransferases and nucleic acid polymerases. 
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Figure S1: UDP-GlcN-BODIPY (2) is a substrate for OGT Glycosylation of a TAMRA-labeled CKII 
peptide acceptor using either UDP (grey), UDP-GlcNAc (blue) or UDP-GlcN-BODIPY (green) was 
monitored by LC/MS after 3 hours incubation at 37°C. a, CKII  (RT = 12.1 min, m/z = 906.2 [M+2H]2+), 
b, CKII-GlcNAc (RT = 11.5 min, m/z = 1007.5 [M+2H]2+), c CKII- GlcN-BODIPY (RT = 13.7 min, m/z = 
1130.5[M+2H]2+). Reaction mixtures consisted of 100 µM nucleotide sugar donor, 100 µM CKII peptide, 
1 µM recombinant OGT, and 5U alkaline phosphatase in PBS containing 12.5 mM MgCl2. LC/MS was 
performed according to the method described in General Procedures (mobile phase H2O/CH3CN + 0.1% 
TFA, 30 to 70% CH3CN over 20 min). 
 
 
Figure S2: The OGT active site accommodates substrate 2 with minimal disruption. A, Structure of 
UDP-GlcNAc bound OGT (PDB= 4gz5, pink for UDP-GlcNAc, green for OGT residues) overlaid onto 
OGT/substrate 2 complex, indicating substrates are similarly positioned except for the α-phosphate. OGT 
structure depicted as translucent cartoon ribbons with residues discussed in main body of text shown in 
orange and substrate 2 in light blue. Hydrogen bonds depicted as black lines.  B, Final 2Fo-Fc electron 
density map for substrate 2. Electron density contoured to 1 σ and depicted as a blue mesh around 
ligands (light blue sticks). 
 
 
Figure S3: The omit Fo-Fc electron density map for the unmodeled BODIPY fluorophore.  Difference 
density contoured to 3 σ and depicted as green mesh above the 5-carbon linker of substrate 2. Difference 
density could not be modelled with confidence, likely attributable to multiple BODIPY conformations. 
 
 
Figure S4: BODIPY-UDP-GlcNAc (2) is processed by OGT in a concentration-dependent manner 
and produces >50-fold signal/background. 100 µM Biotin-CKII peptide was incubated with 200 nM 
OGT in PBS at 37°C for 3 hours. Samples were then transferred to streptavidin-coated microplates, 




Figure S5: UDP concentrations ≥1 mM are sufficient to inhibit 99% of OGT activity, making it 
suitable as a stop reagent for the activity assay. Assay was performed according to the general 
procedure (Supplemental Methods) using 3 µM substrate 2, 12.5 µM Biotin-CKII peptide, and 250 nM 
OGT. Reaction components were combined with various concentrations of UDP and incubated at room 
temperature for 3 hours. Error bars represent S.E.M. of triplicate values. 




































Figure S6: Fluorescent assay permits comparison of OGT-catalyzed glycosylation of various 
peptide acceptors. A, Michaelis-Menten plot detailing glycosylation kinetics of CKII vs TAB-1. OGT 
displays typical Michaelis-Menten behaviour in the presence of these substrates, with similar second-
order rate constants (Table S3). Curves were fitted to a standard Michaelis-Menten equation using 
Graphpad Prism.  B, Michaelis-Menten plot detailing glycosylation of CKII vs HCF-1. Substrate or product 
inhibition was observed for HCF-1 irrespective of enzyme concentration. Reaction progress curves were 
found to be linear for the duration of the read at all concentrations tested. OGT displays a higher affinity 
for this substrate relative to CKII, with a 21-fold difference in second-order rate constants (Table S3). 
Data for HCF-1 was fitted to the equation incorporating substrate inhibition [Y=Vmax*X/(Km + 
X*(1+X/Ki))]. Error bars represent S.E.M. of quadruplicate measurements. 
 
 
Figure S7: UDP inhibits OGT non-competitively with respect to CKII acceptor peptide. Initial rates 
of OGT-catalyzed glycosyation of CKII in the presence of varying concentrations of UDP and CKII, and 
a fixed concentration of UDP-GlcN-BODIPY (30 µM), were transformed into a double-reciprocal plot. Ki 
values were calculated from non-linear regression of Michaelis-Menten curves. Calculated UDP Ki = 15 
µM. Error bars represent S.E.M. of triplicate measurements. 
 
 
Figure S8: Optimization of automated plate washer cycles indicates that a 6 mm aspiration height 
results in excellent signal-to-noise between controls. A lower height setting (3 mm) results in loss of 
overall signal, suggesting that some beads containing glycosylated product are aspirated. 384-well plates 
were washed with 100 µL PBS per cycle using a BioTek EL406 automated plate washer. A final dispense 




Figure S9: The presence of desthiobiotin does not significantly affect assay performance at 
concentrations up to 25 µM. The reported KD for desthiobiotin is approximately 10-11 M [1]. Assay was 
performed according to the general procedure using 3 µM substrate 2, 10 µM Biotin-HCF-1 peptide, and 
20 nM OGT. Reactions were carried out at room temperature for 60 min and were stopped by addition of 
UDP to a final concentration of 2 mM.  Error bars represent S.E.M. of triplicate measurements. 
  
 
Figure S10: Dyngo-4a inhibits OGT non-competitively with respect to both glycosyl donor and 
acceptor substrates. A, Michaelis-Menten plots of UDP-GlcN-BODIPY (2) in the presence of varying 
concentrations of Dyngo-4a (9). Increasing concentrations of 9 result in a reduction of Vmax without 
significantly affecting KM. B, double-reciprocal plot of Michaelis-Menten data demonstrating a non-
competitive pattern of inhibition. C, Michaelis-Menten plots of CKII peptide in the presence of varying 
concentrations of 9, which reduces Vmax but does not affect KM. D, double-reciprocal plot of CKII Michaelis-
Menten data, demonstrating a non-competitive pattern of inhibition. Ki values were calculated from non-




Figure S11: Dyngo-4a does not inhibit OGT in a time-dependent fashion. Enzyme was pre-incubated 
with OGT at 4°C for 0-90 minutes prior to addition of substrate and relative activity was normalized against 




Figure S12: Screening of 167 structurally-related analogues of Dyngo-4a reveals additional 
inhibitors of OGT. Compounds were screened at a final concentration of 40 µM under balanced assay 
conditions identical to those used for high-throughput screening of OGT. Prioritized analogues Dyngo-4-
070 (10) and Dyngo-4-183 (11) are indicated in blue and red font, respectively. Compounds were 
assayed in triplicate; error bars represent S.E.M.   
 
 
Figure S13: Effect of Dyngo analogues on dynamin GTPase activity. A, Dyngo-4-070 (10), B, Dyngo-
4-183 (11). Assay was performed according to the general procedure for in vitro dynamin activity in three 
independent experiments, each with technical triplicates. 
 
 
Figure S14: Optimized conditions for fluorescent activity assay result in robust signal/noise and 
Z’-scores suitable for HTS.  A representative control plate was subjected to identical conditions 
described in the general HTS procedure. Z’ score was calculated according to equation 1 described by 
Zhang  et al.[2]: 
Z' = 1 - 
3 (σc++σc-)
|µc+ -  µc-|
                       (1) 
 
Where σ is the standard deviation of the positive and negative control replicates and µ is the mean of 
the control replicates. Positive controls consisted of reaction wells in the absence of inhibitor; negative 
controls consisted of reaction wells in the absence of enzyme. 
 
 
Figure S15: Conditions used for high-throughput screening result in linear reaction progress 
curves for at least 75 minutes when using 20 nM OGT. Experiments were performed according to the 
general procedure of the OGT activity assay using donor and acceptor substrate concentrations ≈KM (3 
µM and 10 µM, respectively). Wells at various time points were stopped by the addition of an equal 
volume of 7.5 mM UDP to the reaction. Data points represent S.E.M of four replicate measurements.  
 
 
Figure S16: Concentrations of up to 2% DMSO do not significantly affect the performance of the 
fluorescent OGT assay. Assay was performed according to the general procedure using 3 µM substrate 
2, 12.5 µM Biotin-CKII peptide, and 200 nM OGT. UDP was pre-incubated with enzyme at 4°C for 30 min 
prior to addition of substrates. Reactions were carried out at room temperature for 60 min and were 
stopped by addition of UDP to a final concentration of 2.5 mM. Data were fitted to normalized 4-parameter 
sigmoidal inhibition curve using Graphpad Prism 5. Error bars represent S.E.M. of triplicate values. 

















Figure S17: Glycosylation kinetics of HCF-1 are linear over all concentrations of Substrate 2.  Final 
concentration of OGT is 20 nM. Assay was performed according to the general procedure using a fixed 
concentration of HCF-1 peptide (10 µM, ≈KM). Reactions were stopped at various time points with the 






 OGT4.5 with substrate 2 
Accession Code 6TKA 
Data Collection 
Space Group P3121 
Cell Dimensions 
a, b, c (Å) 100.8, 100.8, 132.6 
α, β, γ (°) 90, 90, 120 
Resolution (Å) 87.32 (1.91)* 
Rmerge 0.096 (2.332) 
Rp.i.m 0.03 (0.710) 
I/σI 15.6 (1.1) 
CC1/2 1 (0.405) 
Completeness (%) 100 (100) 
Redundancy 12 (12.3) 
Refinement 
Resolution (Å) 1.91-73.05 
No. of reflections 57876 
Rwork/Rfree 18.4/23.3 









Bond lengths (Å) 0.009 
Bond angles (°) 1.57 
 
Table S1: Data collection of refinement statistics for 6TKA 
 





Table S2: Comparison of Michaelis-Menten kinetic parameters obtained for fluorescent OGT substrate 
2 relative to UDP-GlcNAc using an oligopeptide acceptor in a radioactivity-based assay. Values 
represent the mean ± S.E.M of triplicate values. Reactions were carried out in the presence of 
saturating concentrations of glycosyl acceptor (>10-fold above KM). Reactions using 3H-UDP-GlcNAc 
were previously performed by Lazarus et al.[3] 
 
 
Table S3: Michaelis-Menten kinetic parameters for OGT-catalyzed glycosylation of various peptide 
acceptors. Values represent the mean ± S.E.M of triplicate values. Reactions were carried out in the 
presence of saturating concentrations of fluorescent glycosyl donor (>10-fold above KM). Residues in 


















IC50 13 µM 


















(min-1 µM-1) Relative rate 
{3H} UDP-GlcNAc 2.3 ± 0.4 0.29 ± 0.01 0.12 ± 0.01 6.7 









(min-1 µM-1) Relative  
rate 
CKII YPGGSTPVSSANMM 6.2 ± 0.6 0.068 ± 0.002 0.011 ± 0.001 1 
TAB-1 PVSVPYSSAQSTS 5.6 ± 0.5 0.078 ± 0.002 0.014 ± 0.001 1.3 










IC50  7.1 µM 
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IC50 44 µM 












IC50 35 µM 


















IC50 > 100 µM 
 
 
Table S4: Summary of 11 hit compounds identified as OGT inhibitors from HTS that were re-ordered for 
follow up experiments. All compounds were obtained as dry powders from TargetMol Corp. (Wellesley 
Hills, MA). Compounds were triaged by first determining IC50 values against OGT in the presence of 
0.02% Triton X-100. Five compounds did not show inhibition with re-ordered material and were discarded. 




General Synthetic Procedures 
 
All synthetic reagents used in this study were obtained from Sigma-Aldrich (Oakville, ON), Carbosynth 
(San Diego, CA) or Alfa Aesar (Ward Hill, MA). Anhydrous reactions were carried out in flame-dried 
glassware under a positive pressure of dry argon.  Air- or moisture-sensitive reagents and anhydrous 
solvents were transferred with oven-dried syringes or cannulae.  Flash chromatography was performed 
using E. Merck silica gel (230-400 mesh).  Solution-phase reactions were monitored using analytical thin 
layer chromatography (TLC) with E. Merck 0.2 mm pre-coated silica gel aluminium plates 60 F254; 
compounds were visualized by illumination with short-wavelength (254 nm) ultraviolet light and/or staining 
with ceric ammonium molybdate or potassium permanganate staining solution.  Pyridine was dried 
extensively over activated 4 Å molecular sieves under argon.  Custom synthesis of oligopeptides used 
for activity assays was carried out by Biomatik Corporation (Cambridge, ON, Canada) at >95% purity. 1H 
NMR (600 MHz) and 13C NMR (151 MHz) spectra were recorded at ambient temperature on a Bruker 
Avance II 600 spectrometer equipped with a 5 mm QNP cryoprobe. 1H NMR spectra at 500 MHz and 13C 
NMR spectra at 125 MHz were recorded at ambient temperature on a Bruker Avance III 500 spectrometer 
equipped with a 5mm TXI inverse ATM probe and BACS-60 robotic sample changer. Deuterated 
chloroform (CDCl3), dimethyl sulfoxide (DMSO-d6), methanol (CD3OD) or water (D2O) were used as NMR 
solvents.  Chemical shifts are reported in ppm downfield from tetramethylsilane (TMS) and corrected 
using the solvent residual signal as a reference.  Splitting patterns are designated as follows:  s, singlet; 
d, doublet; t, triplet;  q, quartet;  p, pentet; hex, hextet;  m, multiplet and br, broad.   
 
High Pressure Liquid Chromatography and Mass Spectrometry 
 
Samples were analyzed and purified using an Agilent 1200 HPLC equipped with an Agilent 300SB-C18 
column (9.4 × 250 mm, 5μ particle size).  Compounds were eluted on the column at a flow rate of 2 
mL/min using HPLC grade water and acetonitrile with 0.1% trifluoroacetic acid, or 50 mM aqueous 
ammonium acetate and methanol as the mobile phase. High-resolution mass spectrometry was 
performed using a Bruker maXis Impact UltraHigh-Resolution Quadrupole Time-of-Flight (UHR-QTOF) 
mass spectrometer using a gradient consisting of HPLC grade water and acetonitrile containing 0.1% 
formic acid at a flow rate of 0.3-0.5 ml/min. Ions were sprayed in positive mode with a voltage of 4200 V. 
Nitrogen drying gas was 180°C at a flow rate of 8 L/min. Data was acquired over a mass range of 300-





















































































Scheme S1: Synthetic route towards UDP-GlcN-BODIPY (2). Reagents and conditions: i) imidazole-1-
sulfonyl azide •HCl, CuSO4 •5H2O, K2CO3, MeOH, 2 h, 92%; ii) Ac2O, pyridine, 10 h, 98%; iii) H3PO4 (s), 
vacuum, 60°C, 44%; iv) NaOMe, MeOH, 92%; v) H2, Pd/C, MeOH, 98%; vi) Cpd 10, HBTU, DIPEA, DMF, 

























Scheme S2: Synthetic route towards BODIPY-FL caproic acid. Reagents and conditions: i) DCC, NHS, 
DMF, 75%; ii) Caproic acid, DIPEA, DMF, 91%. 
 
3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α-D-glucopyranosyl phosphate (5) 
Crystalline phosphoric acid (1.9 g, 19.5 mmol) was added to a flame-dried 500 mL round bottom flask 
under an argon atmosphere. 0.9 g (2.4 mmol) of tetra-O-acetyl-2-azido-2-deoxy-D-glucopyranose (4) was 
added, and the mixture was heated to 60°C in a sand bath under vacuum for 4 hours. The mixture was 
then cooled to room temperature and dissolved in 12 mL anhydrous THF. The solution was further cooled 
in an ice bath and then quenched with concentrated aqueous ammonium hydroxide (2 mL) until a pH of 
7 was reached. The ammonium phosphate precipitate was removed by filtration and the filtrate was 
concentrated under reduced pressure. The crude product was purified by flash column chromatography 
(10:3:1 to 10:6:1 EtOAc:MeOH:H2O) to give 5 as a brown solid (0.43 g, 44%). Spectral data were in 
agreement with previous reports[4]. 1H NMR (500 MHz, MeOD): δ (ppm) 5.70 (dd, J = 2.4, 6.8 Hz, 1H), 
5.47 (dd, J = 9.8, 9.8 Hz, 1H), 5.08 (dd, J = 9.8, 9.8 Hz, 1H), 4.33 (d, J = 10.5 Hz, 2H), 4.12 (m, 1H), 3.60 
(d, J = 10.4 Hz, 1H), 2.05 (s, 1H), 2.03 (s, 1H), 2.00 (s, 1H).  
 
2-Azido-2-deoxy-α-D-glucopyranosyl phosphate (6) 
3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α-D-glucopyranosyl phosphate (5) (0.43 g, 1.05 mol) was dissolved 
in anhydrous methanol (10 mL) in a 50 mL round bottom flask. A spatula tip of NaOMe (100 mg, 0.002 
mol) was added to the solution, which was stirred at room temperature overnight. The mixture was 
acidified with Amberlite IR-120 ion exchange resin (H+ form) until a pH of 7 was reached. The solution 
was then filtered and concentrated under reduced pressure to yield 6 as a brown solid, which was carried 
forward without further purification (0.36 g, 92%). Spectral data were in agreement with previous 
reports[4]. 1H NMR (500 MHz, MeOD): δ (ppm) 5.56 (d, J = 3.4 Hz, 1H), 3.99-3.84 (m, 3H), 3.64 (m, 2H), 
3.21 (d, J = 10.4 Hz, 1H). 
 
2-Amino-2-deoxy-α-D-glucopyranosyl phosphate (7) 
Compound 6 (235 mg, 0.83 mmol) was added to a 100 mL round bottom flask. Palladium hydroxide on 
carbon (23 mg, 0.16 mmol), water (10 mL) and  methanol (10 mL) were added, and the flask was charged 
with an atmosphere of hydrogen. The suspension was stirred vigorously for 2 hours at room temperature 
and was then filtered and washed with methanol (20 mL). The filtrate was concentrated under reduced 
pressure to yield 7 as an amorphous solid (215 mg, 92%). 1H NMR (500 MHz, D2O) δ 5.51 (dd, J = 7.6, 
3.3 Hz, 1H), 3.94 (ddd, J = 10.1, 5.1, 2.3 Hz, 1H), 3.87 (dd, J = 12.3, 2.3 Hz, 1H), 3.80 – 3.72 (m, 2H), 
3.42 (dd, J = 10.1, 9.2 Hz, 1H), 2.99 (ddd, J = 10.3, 3.4, 1.8 Hz, 1H). 13C NMR (126 MHz, D2O) δ 92.73, 
72.41, 71.95, 69.98, 60.86, 55.11. HRMS (ESI-) Calculated 258.0378 , found 258.0337 [M-H]-. 
 
2-deoxy-2-N-[6-((4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl)amino)hexanoyl-
α-D-glucopyranosyl phosphate (8) 
To a 100 mL flame dried round bottom flask under an argon atmosphere was added compound 7 (106 
mg, 0.35 mmol), BODIPY-FL-X-OH (S3) (60 mg, 0.15 mmol) and DMF (50 mL). HATU (60 mg, 0.22 
mmol) and triethylamine (140 µL, 1 mmol) were added, and the suspension was stirred vigourously 
overnight at room temperature. The mixture was then concentrated by co-evaporation with toluene (3 x 
50 mL) and was purified directly using flash column chromatography (10:3:1 to 10:60:1 
EtOAc:MeOH:H2O) to yield compound 8 as a red crystalline solid (38 mg, 37%). 1H NMR (500 MHz, 
Methanol-d4) δ 7.44 (s, 1H), 7.02 (d, J = 4.0 Hz, 1H), 6.33 (d, J = 4.0 Hz, 1H), 6.21 (s, 1H), 5.44 (dd, J = 
7.0, 3.4 Hz, 1H), 3.96 (dt, J = 10.6, 2.9 Hz, 1H), 3.92 – 3.81 (m, 2H), 3.73 – 3.63 (m, 2H), 3.36 (t, J = 9.4 
Hz, 1H), 3.23-3.17 (m, 4H), 2.61 (t, J = 7.5 Hz, 2H), 2.51 (s, 3H), 2.28 (d, J = 7.5 Hz, 2H), 2.27 (s, 3H), 
1.64 (dd, J = 9.3, 6.1 Hz, 2H), 1.54 – 1.45 (m, 2H), 1.36 (dd, J = 7.9, 7.7 Hz, 2H). 13C NMR (151 MHz, 
D2O) δ 181.45, 177.39, 174.65, 161.42, 155.61, 146.42, 135.30, 133.11, 128.71, 124.79, 120.97, 116.71, 
93.01, 72.16, 71.27, 70.16, 60.71, 53.94, 39.15, 35.60, 27.97, 25.53, 24.94, 24.35, 14.18, 10.50. HRMS 
(ESI+) Calculated 647.2464, found 647.2471 [M+H]+. 
 
Synthesis of UDP-GlcN-BODIPY (2) 
To a 50 mL flame dried round bottom flask under argon was added compound 8 (32 mg, 0.05 mmol), 
Uridine 5′-monophosphomorpholidate 4-morpholine-N,N′-dicyclohexylcarboxamidine salt (68 mg, 1 
mmol), and N-methylimidazolinium HCl (31 mg, 0.26 mmol) in 5 mL DMF. The solution was stirred 
overnight, concentrated under reduced pressure, and then purified on an Agilent 1200 series HPLC 
equipped with an Agilent XDB-C18 Eclipse reversed-phase column (9.4 × 250 mm, 5μ particle size). 
Mobile phase conditions: 50:50 to 70:30 A:B over 20 minutes, 2 mL/min flow rate,  solvent A = 50 mM 
NH4OAc, solvent B = MeOH, product retention time 17.2 min. The collected material was lyophilized to 
give 2 as a red powder (21 mg, 45%). For long-term storage, the product was kept as a dry powder at -
20°C in a vial which was protected from light. 1H NMR (600 MHz, Deuterium Oxide) δ 7.84 (d, J = 8.1 Hz, 
1H), 7.31 (s, 1H), 6.98 (d, J = 4.0 Hz, 1H), 6.28 (d, J = 4.0 Hz, 1H), 6.20 (s, 1H), 5.82 (d, J = 4.4 Hz, 1H), 
5.80 (d, J = 8.1 Hz, 1H), 5.48 (dd, J = 7.0, 3.3 Hz, 1H), 4.29 (dd, J = 9.0, 5.0 Hz, 1H), 4.26 (dd, J = 9.0, 
5.0 Hz, 1H), 4.22 – 4.18 (m, 2H), 4.16 – 4.13 (m, 1H),  3.98 (dt, J = 10.5, 3.0 Hz, 1H), 3.93 (ddd, J = 10.1, 
4.7, 2.3 Hz, 1H), 3.86 (dd, J = 12.5, 2.3 Hz, 1H), 3.79 – 3.73 (m, 2H), 3.51 (dd, J = 10.1, 9.1 Hz, 1H), 
3.13 (t, J = 6.6 Hz, 2H), 3.11 (t, J = 7.3 Hz, 2H), 2.61 (t, J = 7.3 Hz, 2H), 2.44 (s, 3H), 2.29 (t, J = 7.6 Hz, 
2H), 2.17 (s, 3H), 1.53 (p, J = 7.6 Hz, 2H), 1.42 (p, J = 7.5 Hz, 2H), 1.25 – 1.16 (m, 2H). 13C NMR (151 
MHz, D2O) δ 179.98, 177.48, 174.72, 165.94, 151.46, 141.38, 133.13, 128.82, 124.83, 120.91, 116.68, 
102.30, 94.69, 88.66, 82.95, 73.94, 73.01, 70.94, 69.68, 69.39, 60.40, 53.56, 39.15, 35.53, 34.77, 28.00, 




Synthesis of BODIPY-FL N-hydroxysuccinimidyl ester (S2) 
BODIPY-FL (175 mg, 0.6 mmol), N-hydroxysuccinimide (275 mg, 2.4 mmol), and 
dicyclohexylcarbodiimide (495 mg, 2.4 mmol) were added to a 25 mL flame-dried round bottom flask 
under an argon atmosphere. Anhydrous dimethylformamide (6 mL) was added and the mixture was 
stirred at room temperature for 3 hours. When the reaction was judged complete by TLC, the solvent was 
removed by co-evaporation with toluene and 10 mL EtOAc was added to the flask. The mixture was then 
filtered and the filtrate was purified by flash column chromatography (99:1 DCM:MeOH) to yield S2 as a 
red amorphous solid (220 mg, 75%). 1H NMR (500 MHz, Chloroform-d) δ 7.09 (s, 1H), 6.88 (d, J = 4.0 
Hz, 1H), 6.33 (d, J = 4.0 Hz, 1H), 6.12 (s, 1H), 3.38 (t, J = 7.3 Hz, 2H), 3.08 (t, J = 7.4 Hz, 2H), 2.83 (br 
s, 4H), 2.56 (s, 3H), 2.25 (s, 3H). HRMS (ESI+) Calculated 412.1256, found 412.1252 [M+Na]+. 
 
Synthesis of BODIPY-FL Caproic acid (S3) 
To a flame-dried 50 mL round bottom flask was added compound S2 (220 mg, 0.57 mmol), caproic acid 
(150 mg, 1.14 mmol), and anhydrous DMF (5 mL). Diispropylethylamine (0.2 mL, 1.14 mmol) was added, 
and the solution was stirred at room temperature for 3 hours. The solvent was removed under reduced 
pressure and the materials were dissolved in 10 mL MeOH. Amberlite IR-120 (H+ form, 50 mg) was 
added and the mixture was stirred for 10 min until a pH of ~7 was reached. The mixture was then filtered, 
concentrated, and purified by flash column chromatography (0.5% to 10% MeOH in DCM) to yield S3 as 
a red amorphous solid (220 mg, 96%). 1H NMR (500 MHz, Methanol-d4) δ 7.43 (s, 1H), 7.01 (d, J = 4.0 
Hz, 1H), 6.32 (d, J = 4.0 Hz, 1H), 6.21 (s, 1H), 3.22 (t, J = 7.6 Hz, 2H), 3.19 – 3.15 (m, 2H), 2.60 (t, J = 
7.6 Hz, 2H), 2.51 (s, 3H), 2.30-2.26 (m, 5H), 1.60 (p, J = 7.5 Hz, 2H), 1.49 (p, J = 7.1 Hz, 2H), 1.37 – 
1.31 (m, 2H).13C NMR (126 MHz, MeOD) δ 174.53, 161.30, 158.52, 145.80, 136.50, 134.89, 129.59, 
125.74, 121.32, 117.71, 40.25, 36.05, 30.74, 30.05, 27.50, 25.83, 25.67, 11.17. HRMS (ESI+) Calculated 
428.1933, found 428.1931 [M+Na]+. 
  
Synthesis of Dyngo-4a (9) 
Dyngo-4a was synthesized as previously reported[5]. Characterization data were in agreement with 
previous values. 
 
Synthesis of (E)-N'-(2,5-dihydroxybenzylidene)-3-hydroxy-2-naphthohydrazide (10) 
 
To a solution of 3-hydroxy-2-naphthoic hydrazide (202.2 mg, 1.0 mmol) in EtOH (3 mL) was added 
2,5-dihydroxybenzaldehyde (1.0 eq., 140.0 mg, 1.0 mmol). The reaction mixture was subjected to 
microwave irradiation for 20 min at 120°C. The reaction was allowed to cool, and the resulting precipitate 
collected. The precipitate was washed with chilled EtOH (2 × 4 mL) and chilled Et2O (1 × 4 mL) to afford 
the title compound as a pale yellow-green solid (295 mg, 92%); m.p. >270°C (decomp.). N-acylhydrazone 
compounds exists as syn- and anti-periplanar conformers about the amide CO-NH bond in solution[6]. 
This conformational isomerism is evident in the 1H NMR spectrum for the title compound. Data 
corresponding to the major conformer is reported below. 1H NMR (400 MHz, DMSO-d6) δ 12.08 (br. s, 
1H), 11.35 (br. s, 1H), 10.35 (s, 1H), 9.02 (s, 1H), 8.61 (s, 1H), 8.47 (s, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.77 
(d, J = 8.2 Hz, 1H), 7.52 (dd, J = 8.2, 7.5 Hz, 1H), 7.38 – 7.33 (m, 2H), 7.03 (d, J = 2.1 Hz, 1H), 6.83 – 
6.72 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 163.6, 154.1, 150.2, 149.8, 148.1, 135.8, 130.2, 128.6, 
128.2, 126.7, 125.8, 123.8, 119.8, 119.2, 118.9, 117.1, 113.6, 110.5; LRMS (ESI-) m/z (%): 321 (100) 
(M-H), HRMS (ESI-) m/z calculated for C18H13N2O4 (M-H) 321.0875; found 321.0903. 
 
 
Synthesis of (E)-N'-(2,4,5-trihydroxybenzylidene)benzohydrazide (11) 
 
To a solution of benzohydrazide (149.8 mg, 1.1 mmol) in EtOH (3 mL) was added 
2,4,5-trihydroxybenzaldehyde (1.1 eq., 180.0 mg, 1.2 mmol). The reaction mixture was subjected to 
microwave irradiation for 30 min at 120°C. The reaction was allowed to cool, and the resulting precipitate 















the title compound as a pale yellow solid (232 mg, 77%); m.p. >215°C (decomp.). 1H NMR (400 MHz, 
DMSO-d6) δ 11.80 (s, 1H), 10.63 (s, 1H), 9.56 (s, 1H), 8.56 (s, 1H), 8.45 (s, 1H), 7.91 (d, J = 7.2 Hz, 2H), 
7.61 – 7.50 (m, 3H), 6.88 (s, 1H), 6.34 (s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 162.4, 151.9, 149.3, 




Full-length OGT expression and purification 
The plasmid containing the gene encoding full-length human OGT in a previously-reported pET28a 
vector[7] was transformed into competent Escherichia coli BL21 (DE3) cells (Invitrogen). Successful 
transformants were cultured in Terrific Broth supplemented with 50 µg/mL kanamycin at 37°C until an 
optical density of 1.8 absorbance units was reached. Protein expression was induced with 0.2 mM 
isopropyl β-D-thiogalactoside at 16°C for 18 h. Cells were the harvested and resuspended in 2 mL 
BugBuster protein extraction reagent (EMD Millipore) per gram of cell pellet in the presence of 1 mg/mL 
lysozyme, 0.2 mg/mL DNase and an EDTA-free protease inhibitor tablet (Roche).  The mixture was gently 
rocked at 4°C for 30 min and then clarified by centrifugation for 2 x 30 min at 18,000 x g.  The cell lysate 
was then applied to a 1 mL HisTrap nickel column (GE Healthcare) which was pre-equilibrated in 50 mM 
HEPES, 500 mM NaCl and 1 mM DTT at pH 7.5. The protein was purified using an imidazole gradient of 
20-500 mM over 50 min on an AKTA FPLC (GE Healthcare). Fractions judged as pure were pooled and 
dialyzed at 4 °C in 50 mM HEPES buffer containing 500 mM NaCl and 1 mM DTT at pH 7.4. Aliquots of 
OGT were flash frozen and stored at -80°C for future use. 
 
Truncated OGT expression and purification 
OGT4.5 was expressed in Escherichia coli BL21 (DE3) cells and purified as previously described with a 
few minor changes[3]. Cells were grown to an OD600 of between 1-1.2 in TB media before being cooled to 
16°C for 30 min. Cells were then induced with 0.2 mM IPTG before shaking incubation overnight at 16°C. 
Cultures were pelleted at 5400 x g, and the pellets were resuspended in buffer A (20 mM Tris pH 7.4, 
150 mM NaCl, and 40 mM imidazole), lysozyme, DNAse 1, and 1 mM AEBSF. Cells were lysed by a cell 
disruptor, before being clarified by centrifugation at 41700 x g. Resulting supernatant was loaded onto a 
5 ml HisTrap FF column (GE Healthcare), washed with buffer A, and then eluted with a stepwise gradient 
of buffer B (20 mM Tris 7.4, 150 mM NaCl, and 400 mM imidazole) in buffer A. Fractions containing 
protein were pooled and supplemented with THP to a final concentration of 1 mM. Cleavage of the His-
tag was achieved through incubation with HRV 3C protease at a ratio of 1 μg protease:100 μg protein 
overnight at 4°C. The protein sample was then diluted with 20 mM Tris pH 7.4 to a final concentration of 
15 mM NaCl before being passed over a 5 ml HisTrap FF column (GE Healthcare) and a 5 ml HiTrap Q 
HP column (GE Healthcare). Elution was achieved with a stepwise gradient of 20 mM Tris pH 8.0 through 
to 20mM Tris pH 8 and 1M NaCl. Fractions containing protein were pooled, concentrated using Vivaspin® 
spin-concentrators (Sartorius) and size excluded on a Superdex 200 column (GE Healthcare) in 20 mM 
Tris pH 8.0 and 150 mM NaCl. Monodispersed fractions containing protein were collected, supplemented 
with THP to a final concentration of 1 mM, concentrated and snap frozen. 
 
Crystallisation and structure determination 
Crystals were grown at 20°C using the sitting drop technique with 2 μL of protein/ligand mix and 1 μL of 
reservoir. OGT4.5 (7 mg ml-1) was incubated with UDP (1 mM) for 1 hour, followed by HCF-111-26 peptide 
(3 mM) for 3 hours. Crystals were obtained in 1.45 M potassium sodium tartrate and 0.1 M Tris pH 8.5, 
similar to those previously reported[8]. Crystals were soaked with 750 μM substrate 2, 1 mM MgCl2 and 
7.5 U of calf intestinal alkaline phosphatase in mother liquor for 4 hours. Crystals were cryo-protected in 
mother liquor supplemented with 27% xylitol and flash cooled. Diffraction data was collected at the 
Diamond Light Source in Oxford, UK on beamline I04-1. Data reduction and processing was completed 
through the DIALS pipeline[9]. A previously obtained OGT4.5 structure (4n39) was used as a search 
model for molecular replacement through PHASER[8]. Model building and refinement consisted of multiple 
cycles of manual adjustments in COOT[10] and refinement in REFMAC5[11]. Geometric restraints for 
substrate 2 were generated through AceDRG[12]. Structure figures were produced with Chimera[13] and 
Pymol[14]. 
 
Fluorescent OGT activity assay 
Assays performed manually for assay development or enzyme characterization carried out in black Nunc 
96- or 384-well microplates (cat. # 237108 or 262260, Thermo Fisher Scientific, Mississauga, ON). All 
reported concentrations represent final assay conditions unless otherwise specified. Microplates are 
typically centrifuged at 300 x g for 1 min after addition of reagents. In a typical 384-well experiment, a 
master mix containing various concentrations of fluorescent substrate 7c and biotinylated peptide 
acceptor is made up in PBS containing 12.5 mM MgCl2 and 1 mM DTT at pH 7.2. The reaction is 
commenced by the addition of recombinant OGT PBS to a final well volume of 25 uL and final OGT 
concentration of 20-200 nM. The plate is then incubated at ambient temperature for up to 60 min, during 
which time the reaction rate was shown to be linear (Figure S15). The reaction is terminated by the 
addition of 25 µL stop mix containing 7.5 mM UDP and 0.2 mg/mL streptavidin-coated magnetic beads 
(Trilink Technologies M-1002). The plate is incubated at room temperature for at least 30 min to allow for 
streptavidin-biotin binding, and is then subjected to an automated washing procedure using a BioTek 
EL406 plate washer containing a magnetic adapter and a BioTek 384F magnet (12 wash cycles, 100 µL 
PBS dispensed per well, 6 mm aspiration height offset, 4 min initial resting time on magnet, 1 min rest 
between washes). At the end of the wash cycle, a final dispense of 50 µL PBS per well is performed 
using the syringe dispenser of the BioTek washer. The fluorescence signal is read using a Biotek Neo2 
multimode plate reader using 490nm excitation and 525 nm emission wavelengths. Each well is read 
using an area scan function which records the mean signal of 9 individual scans in a grid pattern with 1.0 
micron spacing between each point. Data were analyzed and plotted using GraphPad Prism 5. 
 
In vitro OGT inhibition assays 
IC50 experiments were carried out using the general procedure for the OGT activity assay, with the 
following modifications. Inhibitor stocks in DMSO were diluted to various concentrations and were pre-
incubated with recombinant OGT on ice for at least 15 minutes. The reaction was commenced by addition 
of a master mix containing both donor and acceptor substrates at their respective KM values. Reactions 
proceeded at room temperature for < 60 min, during which the reaction progress was shown to be linear 
(Figure S15). The % relative activity of OGT in the presence of inhibitor was assessed by normalizing 
fluorescent signal against controls which contained only DMSO (100% activity) and controls which 
contained 2 mM UDP (0% activity). % activities were plotted as a function of log10 concentration of 
inhibitor. Curves were fitted using a sigmoidal 4-parameter log(inhibitor) vs response function in 
GraphPad Prism 5; IC50 values were calculated from the inflection point of sigmoidal curves. Full Ki 
inhibition experiments were carried out in a similar manner, except that the concentration of substrate 
was varied to at least 5-fold above and 5-fold below the KM (app) in the presence of varying concentrations 
of inhibitor. Ki values were calculated using the non-linear regression function of GraphPad Prism 5. 
 
Automated High-Throughput Screening  
Optimization and validation of the OGT activity was performed to ensure suitability for HTS using 
conditions identical to those implemented during screening. Signal-to-background ratio, Z’-scores, DMSO 
tolerance to 2%, and linearity of reaction profiles were assessed in 384-well plates (Nunc; cat. # 262260). 
Assays were run under balanced conditions[15] wherein concentrations of donor and acceptor substrates 
at their KM (app) values were used in the presence of 20 nM recombinant OGT. Buffer used for screening 
consisted of PBS at pH 7.2 supplemented with 12.5 mM MgCl2, 1 mM DTT and 0.01% Triton X-100. 
Library compounds were tested at a final concentration of 100 µM (DMSO 1% final concentration). 
Automated HTS was carried out using Momentum laboratory automation workflow software equipped 
with a Spinnaker BenchTrack 4-axis microplate robot (Thermo Fisher Scientific, Mississauga, ON). 
Solutions of substrate and enzyme were dispensed with a Multidrop Combi (Thermo Fisher Scientific) to 
a final volume of 25 µL. Compounds were added to assay plates using a 384-well pin tool equipped with 
slotted 200 nL pins (FP3NS200, V&P Scientific) and a Freedom EVO 100 (TeCan, Morrisville, NC) liquid 
handling system which was calibrated to transfer 250 nL of 10 mM compound stocks in 100% DMSO. 
Plates were centrifuged at 300 x g for 20 seconds after dispensing and were then incubated at room 
temperature for 60 min. Reactions were stopped by addition of 25 µL stop solution described above using 
the peristaltic pump dispenser equipped with a 5 uL cassette of an EL406 combination washer/dispenser 
(BioTek, Winooski, VT). Plates were incubated for a further 30 minutes at room temperature and then 
subjected to an automated wash cycle and fluorescence detection as described previously. Z’-scores for 
each plate were calculated from the mean % response of the control population and standard deviation 
of the control population according to equation (1). Data from plates which showed Z’-scores ≥ 0.5 were 
retained for analysis and hit confirmation. The hit selection cutoff for inhibitors was set as 3 standard 
deviations from the % activities of the uninhibited controls. Hit confirmation in triplicate was carried out 
using identical conditions as primary screening. Hit population and distribution was visualized using 
GraphPad Prism 5. Hits were triaged computationally using the PAINS and Toxicophore filters using the 
online service FAFDrugs-4[16]. 
 
Differential Scanning Fluorimetry  
Differential Scanning Fluorimetry was performed using an Applied Biosystems QuantStudio 3 RT-PCR 
machine equipped with a 96-well heating block. Reactions were performed in MicroAmp 96-well optical 
PCR plates (Applied Biosystems) at a final volume of 20 µL per well. Reactions contained 0.6 mg/mL 
protein, 1X Protein Thermal Shift Dye (Thermo Fisher Scientific) and 0.2- 100 µM final concentration of 
ligand in 1X PBS. Reaction components were made up on ice; thermal shift assays were carried out at 
temperatures ranging from 25 to 95°C at a ramp rate of 0.05°C/sec. Fluorescence measurements were 
taken using a 580 nm excitation / 623 nm emission filter set. Reactions were performed in triplicate and 
data were analyzed using QuantStudio Design and Analysis software and GraphPad Prism 5. Melt curves 
were fitted to a Boltzmann sigmoidal curve and apparent Tm values were determined by calculating the 
inflection point of the fitted curves. 
In vitro dynamin activity assay 
Dynamin GTPase activity (and the impact of small molecule inhibitors; 0-100 µM) was measured in vitro 
using an adaptation of the Malachite Green phosphate detection absorbance-based assay within a 96-
well plate format as described previously[17]. Dynamin solution (30 µL) was added to reaction buffer 
mixture (120 µL) to yield a final reaction of: 150 µL well volume, 20 nM recombinant full length human 
dynIba, 11 mM Tris-HCl, 30 mM NaCl, 150 µM GTP, 4 µg/mL PS liposomes, 1.6 mM MgCl2, 0.06% 
Tween-80, 0.1 μM AEBSF, 1 μg/mL leupeptin, pH 7.4. Salt-adjusted buffer, basal dynamin and drug 
alone controls were included with each experiment to make the relevant absorbance subtractions. Plates 
were then incubated at 37oC for 30 min with shaking at 800 rpm. The assay was stopped, by sequestering 
magnesium ions, using 0.5 M EDTA (10 µL) followed by the addition of Malachite Green solution (40 µL; 
2% (w/v) ammonium molybdate tetrahydrate, 0.15% (w/v) Malachite Green, 4 M HCl) to react with free 
inorganic phosphate. The absorbance (650 nm) was measured and raw data exported to Microsoft Excel 
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